That is necessary, since the method a protein in the body folds identifies if a pharmaceutical will be able to bind to that protein and be efficient. To put it simply, we have to understand how these proteins fold if we desire a drug to work. Historically, this has been a trial-and-error process (second wave). However now, Alpha, Fold can anticipate protein folding with 92. 4% precision. That's going to make it a lot easier to develop drugs that do what they're created to do. This was a development nearly no one observed. However it's going to have extensive implications for treating disease. I predict that Alpha, Fold will be 98% accurate by the end of 2021.
And, naturally, there will be lots of investment opportunities in this area, too. Moving topics It's going to be an excellent year for bitcoin. I'm bullish on it in 2021 (last week). That stated, I still think bitcoin will continue to be unstable. We're close to all-time highs. I wouldn't be amazed if it pulled back perhaps substantially prior to going higher - jeff brown tech stock 2021. I've been covering bitcoin for a long period of time now. Among the first research study reports I ever published was on bitcoin. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
But at the time of that preliminary recommendation, I entitled my report "What's the Big Offer With Bitcoin?" That shows you where the conversation was at the time. We were mainly informing readers. But that's not the huge question any longer. Now we're seeing institutional money finally take an interest in bitcoin. Massachusetts Mutual Life Insurance took a $100 million stake in bitcoin in December. This is not some small, specific niche enterprise. Mass, Mutual is a relied on 170-year-old institution. So think about that. In 5 years, we went from informing readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake.
Which's a big reason I'm bullish on it this year. first lady. Regards, Jeff Brown, Editor, The Bleeding Edge I have a bonus forecast 2020 was a record year for IPOs. 552 U.S. business went public the most in more than 20 years. These companies raised an overall of $172 billion. That's an all-time high beating the previous yearly record by 43%. I forecast 2021 will be another record year in IPOs. There are numerous great personal companies on the verge of striking the general public markets And I have actually been working on a new method for you to invest even before these business go public.
This opportunity has been constructing over the last couple of years. I can't wait to inform you everything about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Event to learn all the information. Go right here to reserve your spot totally free.
Emma Walsh here, managing editor of the Journal. Regular Diary readers know that tech isn't our typical beat (self-driving cars). And when it concerns tech investing, we leave it to the specialists. Thankfully, we have numerous such professionals in our Rolodex. Our colleague Jeff Brown will be familiar to our long time readers. He is one of the most accomplished tech investing professionals we understand (last year). In fact, he had numerous triple-digit returns in his Brownstone Research portfolios last year. Here's what Jeff believes the tech sector will bring us in 2021 Each year, I like to have a look at the big photo and forecast what's simply around the corner.
That consists of things like 5G networks, biotech, expert system, and a lot more. These trends are experiencing exponential growth and creating amazing opportunities for financiers. I desire to ensure all our readers are prepared for what's next. And with that in mind, let me draw the image of what I see being available in the next 12 months Our new 5G (fifth-generation) cordless networks are a topic I have actually been covering for years now. brownstone research. But in spite of what many readers may believe, this is a pattern that's just getting going. Even though the COVID-19 pandemic interfered with supply chains last year, an impressive 250 million 5G-enabled devices were still sold.
And all of this eventually resulted in Apple postponing the release of the 5G-enabled i, Phone 12 by two months (jeff brown biotech pick). Losing two months of manufacturing and sales truly affects how numerous 5G devices are offered in the fiscal year. When you consider all of that, offering 250 million systems is remarkable. More importantly, the delays triggered by the pandemic produced a lots of bottled-up demand. And that demand is now going to be pressed into 2021. In truth, I anticipate that more than 500 million 5G gadgets will be shipped in 2021 - united states. Which's not my only 5G prediction When I've spoken about 5G in the past, I have actually explained its three various stages.
In Stage 2, 5G gadgets go on sale. 5G phones and other items begin to reach consumers. And in Stage Three, 5G services start to be used (exponential growth). That's when we begin to see applications operating on 5G networks. Think about things like huge multiplayer games over a cellphone. That's not possible with 4G. It will be with 5G. And my second 5G forecast for 2021 is that we will start Phase Three by this summertime. This begins something of a virtuous cycle: A lot of individuals don't truly appreciate the technology. But they will care if there are amazing applications that can just be accessed with a 5G phone.
That leads to more 5G apps being developed. In truth, 5G is going to open a suite of amazing applications: self-driving vehicles, the Internet of Things, robotic surgical treatment, and more. All of these innovations need 5G. The financial investment opportunities moving forward will be enormous. Stepping far from 5G, the next crucial innovation I predict in 2021 is CRISPR genetic modifying. CRISPR stands for "clustered frequently interspaced short palindromic repeat." It's a mouthful. But it's one of the most amazing advancements in biotechnology. At a high level, CRISPR is a technology that can edit our hereditary makeup as if it were software.
The program can crash or not operate correctly. CRISPR uses a comparable idea but with our genetic code. "Typos" in our genome can lead to disease. CRISPR can fix these "typos." For several years, CRISPR was mostly a niche innovation that wasn't well comprehended. And during that time, there were truly only three companies operating in this area. However things are changing. CRISPR is no longer simply theoretical. We're seeing actual results. We're dealing with diseases and seeing that this innovation just works. And as a result, a "second crop" of early-stage CRISPR business is going public and delivering amazing returns. This entire industry is effectively a greenfield chance.
There's room for lots of companies to exist in this space. social media. And there will be more. That's my prediction for CRISPR in 2021. I anticipate that two or 3 more hereditary editing companies will hold their IPOs. Sticking to biotechnology, we are seeing remarkable things taking place at the merging of biotech and expert system (AI). Google's AI subsidiary, Deep, Mind, just revealed at the end of 2020 that its latest Alpha, Fold software application can properly predict the folding of a protein based solely on its amino acid sequence with 92. 4% precision. That's crucial since the method a protein in the body folds figures out if a pharmaceutical will be able to bind to that protein and work.
Historically, this has been a trial-and-error process. But now, Alpha, Fold can forecast protein folding with 92. 4% accuracy. That's going to make it much simpler to develop drugs that do what they're developed to do. And here's my next forecast. I anticipate that Alpha, Fold will be 98% precise by the end of 2021. And we will see not just one however a number of drug treatments produced utilizing this innovation. This was one of those breakthroughs that practically nobody discovered. But it's going to have profound implications for treating illness. And, obviously, there will be lots of financial investment opportunities in this space, too.
It's going to be a great year for bitcoin. I'm bullish on it in 2021. That said, I still believe bitcoin will continue to be unstable. We're close to all-time highs. I wouldn't be shocked if it pulled back possibly considerably prior to going higher. I have actually been covering bitcoin for a long period of time now. One of the very first research study reports I ever published was on bitcoin - second wave. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ roi for any person who followed my suggestion. However at the time of that preliminary recommendation, I titled my report, "What's the Big Offer With Bitcoin?" That shows you where the conversation was at the time.
However nobody is asking that question any longer. Now, we're seeing institutional cash finally taking an interest in bitcoin. The huge news was that Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some small, specific niche business. bleeding edge. Mass, Mutual is a 150-year-old institution. So consider that. In 5 years, we went from educating readers on what bitcoin is to a business like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. And that's a huge reason why I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have another bonus offer forecast In 2021, we're going to have another record year in IPOs. One website reports that Jeff Brown deserves about $27. 5 million and declares the details is up to date since February 2021, however we might not independently verify this claim. Provided Jeff Brown's past, he likely has a considerable net worth, but we can't hammer down a precise figure at this minute. Brown is best understood for his sage-like ability to select winning innovation stocks. He invested more than 25 years researching innovation companies like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's extensive experience gives him an excellent point of view on the marketplace. He's constantly on the hunt for brand-new opportunities, and he shares a number of his finest picks in the Future Report.
That's high praise, but it's not absurdly reasoned. Brown has an outstanding reputation as a stock-picker, and he effectively forecasted some of the biggest economic occasions of the past twenty years. Although he does not appear to release his choices to the public, the service's success is a direct indication of Brown's stock-picking expertise. Nobody on Wall Street gets it right whenever, but Jeff Brown's accurate forecasts have earned him legions of devoted followers. That says a lot about his ability. The Future Report is released by Brownstone Research, a popular financial research study publisher. Brownstone Research study uses a number of research study services with a wide range of expertises - biotech stock.
The company is likewise associated with Bonner & Partners, another well-respected research publisher - last week. On its website, Brownstone says its objective is to offer retail investors with professional-grade research: "For too long, the finest financial investment research has not been available to specific investors. It has been generally booked for financial investment banks, hedge funds, personal equity, and high-net-worth clients. jeff brown latest prediction. The objective of Brownstone Research is to make that kind of proprietary research available to any investors wanting to acquire an edge in the marketplaces. The goal is simple to provide unique and profitable investment research study found nowhere else." -Brownstone Research website excerpt from the Jeff Brown is the creator of Brownstone Research, and he also serves as the firm's Chief Investment Expert.
With Brown assisting the ship, Brownstone Research study is a powerhouse publisher with lots to offer its clients. After decades of constant success at the helm of top-tier companies like Tesla and Area, X, Elon Musk is a home name throughout the majority of America. If you understand even a little bit about the marketplace, you understand that he has a credibility as a King Midas of sorts. jeff brown 1 biotech company. Everything he touches turns to gold! Jeff is well mindful of Elon Musk's executive expertise, so he constantly has an eye out for the Silicon Valley rock star's next move. This time, Jeff has an early lead on Elon's next huge project.
In truth, Brown thinks S.A.V. genetic sequencing companies jeff brown. might be "the biggest pattern of the 2020s, and he's not alone. Inspect out these quotes from other well-known S.A.V. bulls: Elon's next big act will be weding two innovative technologies: synthetic intelligence and electrical cars. Musk hopes the combination will assist him establish the very first fully-autonomous, self-driving automobiles ever. It's nothing short of the automotive market's Holy Grail. As you understand, electric lorries and self-driving car stocks have been huge this year, however the Wall Street maker has actually approved buzz without much concrete outcome. Despite an extreme boost in competitors over the previous few years, Brown still thinks Musk has the best possibility of putting everything together.
tech might be the magic string that connects all of it together. S.A.V. represents Shared Autonomous Vehicle, and it might be the future of transport. Generally, this innovation would enable you to rent your automobile as an autonomous, self-driving taxi when you're not using it. You just leave the cars and truck and press a button on an app that tells the cars and truck to "sign up with the fleet." Next thing you understand, you're unwinding on your couch while your cars and truck shuttles ride-sharers around town. Most importantly, you get to keep a significant piece of the profits. It sounds crazy, but it might be closed than you think.